The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

Eli Lilly stock rose early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest ...

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.